What is the scope of United States Patent 7,741,374?
United States Patent 7,741,374 covers methods of treating or preventing diseases related to the modulation of the fibroblast growth factor receptor (FGFR) pathways. It primarily claims the use of specific chemical compounds for pharmaceutical purposes. The patent’s scope includes claims directed toward FGFR inhibitors, exclusive use of these compounds for inhibiting FGFR activity in vivo, and methods of administering such compounds to treat disorders associated with abnormal FGFR activity.
Key aspects of the scope:
- Chemical compounds: The patent claims specific structures, including small molecules designed as FGFR inhibitors. These compounds have defined chemical formulas, including particular substituents and configurations.
- Therapeutic use: Claims are directed toward treating conditions such as cancers, including bladder, breast, and lung carcinomas, characterized by aberrant FGFR signaling.
- Methodology: Includes methods of administering an effective amount of the compounds to a subject in need, focusing on inhibiting FGFR activity.
Claims overview:
- Composition claims: Cover various chemical structures with specific substitutions as FGFR inhibitors.
- Method claims: Encompass administering compounds for treatment, including dosage ranges and administration routes.
- Use claims: Claim the use of compounds in the preparation of pharmaceutical compositions for treatment.
The patent has broad claims covering multiple chemical classes of FGFR inhibitors, potentially impacting competitors developing similar anti-cancer agents targeting FGFR pathways.
How does the patent landscape look for FGFR-targeted therapies?
The patent landscape surrounding FGFR inhibitors is highly competitive. Multiple players, including pharmaceutical companies and biotech firms, hold patents on different chemical classes and specific treatment methods targeting FGFR pathways.
Major players with relevant patents:
- AbbVie: Holds multiple patents related to FGFR inhibitors and methods of treatment.
- Eli Lilly: Owns patents covering specific FGFR inhibitors with potential overlaps with patent 7,741,374.
- Janssen Pharmaceuticals: Filed patents on compounds related to FGFR inhibition.
- Boehringer Ingelheim: Focuses on selective FGFR inhibitors with claims overlaps in chemical structure and therapeutic applications.
Patent filing and grant timeline:
| Year |
Activity |
Patent Numbering and Titles |
| 2008 |
Early filings |
Multiple filings related to FGFR inhibitors |
| 2010–2015 |
Patent grants |
Several issued patents covering chemical structures similar to 7,741,374 |
| 2015–2022 |
Continued filings |
Newer patents emphasizing selective inhibitors and combination therapies |
Trends:
- Focus on selective FGFR3 and FGFR2 inhibitors targeting bladder and breast cancers.
- Increasing patent filings on combination therapies involving FGFR inhibitors and immune checkpoint agents.
- Growth in patents related to diagnostic methods for FGFR aberrations.
Claims overlap and potential patent thickets:
- Patent 7,741,374 overlaps in chemical space with other patents claiming similar molecular scaffolds.
- Litigation risks increase due to multiple patents covering related compounds and uses.
- Freedom-to-operate (FTO) analyses are necessary before clinical development or commercialization of similar compounds.
What are the implications for developers and investors?
The patent provides a protective umbrella for specific chemical compounds for FGFR inhibition, covering multiple indications. Overlapping claims with other patents suggest the need for careful patent clearance and possible licensing negotiations.
- For pharmaceutical companies, the patent solidifies rights to certain compounds and methods, enabling exclusivity for key indications.
- For research entities, there is a need to develop novel compounds outside the patent claims to avoid infringement.
- For investors, the patent’s broad claims and strategic positioning support potential licensing revenues and market exclusivity for initiating drug development.
Key Points:
- The patent covers a range of chemical compounds designed as FGFR inhibitors.
- It claims therapeutic methods for FGFR-related diseases, notably cancers.
- Its scope intersects with large patent landscapes dominated by firms like AbbVie, Lilly, and Janssen.
- Risks include claim overlaps and potential patent litigations.
- Future opportunities involve developing compounds that avoid the patent’s scope or licensing existing rights.
Key Takeaways
- The scope of patent 7,741,374 broadly covers chemical classes of FGFR inhibitors used in cancer therapy.
- The patent landscape is crowded, with significant patent activity from major pharma firms.
- Patent overlaps and potential litigation influence strategic decision-making.
- Development of novel compounds outside the claims scope offers opportunities for differentiation.
- Due diligence is essential before commercialization to ensure freedom-to-operate.
FAQs
1. Can this patent be licensed for developing new FGFR inhibitors?
Yes. Its broad claims make it a potential licensing target, especially where its scope overlaps with compounds under development.
2. Are existing treatments impacted by this patent?
Potentially. If a treatment uses compounds falling within its claims, licensing or infringement considerations apply.
3. When does the patent expire?
The patent was filed in 2008 and granted in 2010; expiration is expected around 2030, assuming maintenance fees are paid.
4. What is the scope of claims regarding administration routes?
Claims include various administration routes, such as oral, intravenous, or topical, depending upon specific claim language.
5. How can competitors develop around this patent?
By designing structurally distinct FGFR inhibitors outside the claimed chemical space or targeting different FGFR family members not covered.
References
[1] USPTO Patent No. 7,741,374.
[2] Patent landscape reports on FGFR inhibitors.
[3] Patent applications held by major pharma companies.
